Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00234845 · ClinicalTrials.gov registry record · Phase 3
Adalimumab in Combination With Methotrexate vs Methotrexate Alone in Early Rheumatoid Arthritis
A Phase 3 study, sponsored by Abbott.
- Completed
- Registry status
- Phase 3
- Development phase
- 148
- Enrollment target
NCT00234845 is a Phase 3 study that has completed, run by Abbott. The registered enrollment target is 148 participants.
The verdict
NCT00234845, a Phase 3 study, has completed, sponsored by Abbott.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 148 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate the effectiveness of adalimumab in combination with methotrexate compared to methotrexate alone on work disability in subjects with early rheumatoid arthritis
Interventions
- DRUG methotrexate
- DRUG adalimumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 148 participants |
| Start Date | 2003-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00234845
The ClinicalTrials.gov registry entry for NCT00234845 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 148 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abbott, which has 181 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which methotrexate is the first listed.
NCT00234845 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00234845 about?
NCT00234845 is a clinical study titled "Adalimumab in Combination With Methotrexate vs Methotrexate Alone in Early Rheumatoid Arthritis". The purpose of the study is to evaluate the effectiveness of adalimumab in combination with methotrexate compared to methotrexate alone on work disability in subjects with early rheumatoid arthritis
What is the current status of trial NCT00234845?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 148 participants. The study started on 2003-03.
What interventions are being tested in trial NCT00234845?
The interventions under investigation include: methotrexate (DRUG), adalimumab (DRUG).
Who is sponsoring clinical trial NCT00234845?
This trial is sponsored by Abbott, which has 181 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.